This article is more than 5 years old. Information may no longer be current.

BioPharmX advances topical acne solution program with pre-IND FDA approval meeting

BioPharmX has completed its pre-investigational new drug meeting with the FDA for the development of its topical acne compound program, according to a company release.

The meeting focused on the company’s proposed strategy for advancing the program, in addition to its plans for safety and toxicology studies and human clinical trials, the release stated.

“Based on our discussions with the FDA, we are encouraged to continue to advance the development of our topical antibiotic acne compound,” Jim Pekarsky, CEO and co-founder of BioPharmX, said in the release.

With the FDA guidelines, the company plans to advance toward an investigational new drug application for phase 2 clinical trials in the program, according to the release.

Reference: www.biopharmx.com.